The development of cyclotron-based radiopharmaceuticals: a comprehensive review of .sup.64Cu and .sup.123I-radiolabeled urea-based small molecule PSMA ligands

.sup.64Cu and .sup.123I are attracting attention in taking up their role in the development and practical use of PSMA-targeting radiopharmaceuticals. The development of urea-based small molecule PSMA ligands labeled .sup.64Cu and .sup.123I has been progressing steadily with the challenge of obtainin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of radioanalytical and nuclear chemistry 2023-09, Vol.332 (9), p.3523
Main Authors: Hasnowo, Lutfi A, Larkina, Maria S, Garapatski, Alexander A, Yusubov, Mekhman S
Format: Article
Language:English
Subjects:
Nuclear energy
Prostate cancer
Urea
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:.sup.64Cu and .sup.123I are attracting attention in taking up their role in the development and practical use of PSMA-targeting radiopharmaceuticals. The development of urea-based small molecule PSMA ligands labeled .sup.64Cu and .sup.123I has been progressing steadily with the challenge of obtaining optimal performance as PSMA-targeting radiopharmaceutical for prostate cancer. In this review, the authors provide an overview of recent research projects and future directions for the production of cyclotron-based medical radioisotopes .sup.64Cu and .sup.123I, and their application in the development of urea-based small molecule PSMA ligands labeled .sup.64Cu and .sup.123I as radiopharmaceuticals for prostate cancer.
ISSN:0236-5731
DOI:10.1007/s10967-023-09048-3